Velutinam is a potent kinase inhibitor, with IC50 values of 0.6 μM against DYRK1A and 1.5 μM against CDK1/cyclin B [33], which makes the species particularly promising against neurodegenerative disorders such as Alzheimer's disease, in which those targets contribute to tau pathology and neuronal dysfunction. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.